S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX

Benzer Materyaller

• S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
  Yazar:: Gili Kenet, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• SAFETY AND EFFICACY OF THE FITUSIRAN REVISED ANTITHROMBIN-BASED DOSE REGIMEN IN PEOPLE WITH HAEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORS (ATLAS-OLE)
  Yazar:: Guy-Young, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-10-01)
• Study on the nasal drug delivery system of PPX microcapsules
  Yazar:: in situ thermosensitive gel Lin Ma, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-09-01)
• HTRS2025.P2.64 Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A or B on Fitusiran Antithrombin-Based Dosing Regimen (AT-DR): ATLAS-OLE
  Yazar:: Amy Chen, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-11-01)
• Evaluation of Unfavorable Cardiovascular and Metabolic Risk Factors in Children and Young Adults with Haemophilia
  Yazar:: Melek Yıldız, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-06-01)